<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552275</url>
  </required_header>
  <id_info>
    <org_study_id>2020P001793</org_study_id>
    <nct_id>NCT04552275</nct_id>
  </id_info>
  <brief_title>The HALT Biomarker Study</brief_title>
  <acronym>HALT</acronym>
  <official_title>Circulating Biomarkers of Hypo-Attenuated Leaflet Thickening After Transcatheter Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minneapolis Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the HALT Biomarkers study are to identify a panel of circulating proteins that&#xD;
      discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT) and&#xD;
      can be used to supplement the diagnosis of HALT; to characterize changes in circulating&#xD;
      proteins after treatment of HALT with systemic anticoagulation; and to identify circulating&#xD;
      proteins that predict the occurrence of HALT.&#xD;
&#xD;
      The study population will be adult patients undergoing transfemoral transcatheter aortic&#xD;
      valve replacement (TAVR) for severe aortic stenosis (AS) or bioprosthetic valve degeneration.&#xD;
      Enrollment will continue until 30 patients with HALT are identified for completion of phase&#xD;
      1. Based on a HALT incidence rate of 10%, we anticipate enrolling 300 patients.&#xD;
&#xD;
      Patients are enrolled prior to undergoing transfemoral TAVR. Blood samples, clinical data and&#xD;
      echocardiograms will be collected at the following timepoints: baseline (pre-TAVR, T0),&#xD;
      post-TAVR (pre-discharge, T1), 30-day follow-up (window 3-9 weeks, T2), and 6-month follow-up&#xD;
      (T3). Cardiac 4D CT will be performed at the 30-day follow-up visit to screen for the&#xD;
      occurrence of HALT.&#xD;
&#xD;
      Patients with HALT will be treated with systemic anticoagulation for 5-6 months, at which&#xD;
      point a follow-up CT scan and blood sample will be obtained. Control subjects will also&#xD;
      undergo a 6-month study visit with blood sample collection. The study will be conducted&#xD;
      within two phases. Phase 1 will serve as a derivation / discovery study in which candidate&#xD;
      protein biomarkers of HALT will be identified.&#xD;
&#xD;
      Once this is successfully completed, a second cohort will be enrolled within phase 2. Phase 2&#xD;
      will be performed under the auspices a future contract or amendment and will seek to&#xD;
      cross-validate the initial study findings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">June 22, 2035</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2030</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Derivation of the panel of circulating proteins indicative of HALT</measure>
    <time_frame>6 months</time_frame>
    <description>1. Establish the incidence of similar proteomic profiles and the rate to which the profile occurs in TAVR recipients with HALT via a high-throughput precision proteomics platform which utilizes the proximity extension assay (PEA). PEA merges a dual-recognition antibody-based immunoassay with quantitative real-time PCR that allows for the simultaneous quantification of 92 proteins. We will focus on the 5 highest yield panels for the current investigation: cardiovascular II, cardiovascular III, cardiometabolic, inflammation, and oncology II panels. These panels will allow for the assessment of 460 circulating proteins.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish the rate at which these characteristics indicative of future HALT</measure>
    <time_frame>6 months</time_frame>
    <description>Using data analysis of baseline patient characteristics to establish the rate that they are indicative of future HALT in patients with aortic stenosis. The sampling frame assumes the sequencing of 460 proteins; a 5% False Discovery Rate; a 10% prognostic prevalence; a minimum fold change of 2; and a normalization ratio of 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cross-validation of the panel of circulating proteins indicative of HALT</measure>
    <time_frame>6 months</time_frame>
    <description>3. Using 20 matched pairs of subjects with and without HALT, the derivation of the HALT indicative panel of circulating proteins gathered through PEA will be cross-validated using data analysis to establish the rate to which the panel is present in both cohorts. This rate will be used to determine if the proteomic profile of a patient can be used as a diagnostic test for the presence of HALT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Hypo-attenuated Leaflet Thickening</condition>
  <condition>Bioprosthetic Valve Degeneration</condition>
  <arm_group>
    <arm_group_label>HALT Cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who develop HALT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who do not develop HALT</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Proteomics Analysis</intervention_name>
    <description>Determine a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT)</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>HALT Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 65 years&#xD;
&#xD;
          2. Subject with severe native AS or severe bioprosthetic valve degeneration&#xD;
&#xD;
          3. Subject undergoing transfemoral TAVR using a Medtronic Evolut R, Evolut Pro or Evolut&#xD;
             Pro+ transcatheter heart valve&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic anticoagulation therapy&#xD;
&#xD;
          2. Contraindication to systemic oral anticoagulation therapy&#xD;
&#xD;
          3. Chronic kidney disease with EGFR&lt;30 ml/min&#xD;
&#xD;
          4. Bleeding diathesis or known coagulopathy&#xD;
&#xD;
          5. Hypercoagulable state&#xD;
&#xD;
          6. Life-expectancy &lt;12 months due to other medical conditions (e.g., malignancy, severe&#xD;
             Alzheimer's disease, etc.)&#xD;
&#xD;
          7. The patient is currently participating in another investigational device or drug study&#xD;
             that has not reached its primary objective/endpoint&#xD;
&#xD;
          8. Pregnant, lactating, or planning pregnancy within next 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roukoz Abou Karam</last_name>
    <email>raboukaram@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paris J Jamiel, BS</last_name>
    <phone>(617) 726-0996</phone>
    <email>pjamiel@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>SELMARIAH@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sammy Elmariah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>Santiago.Garcia@allina.com</email>
    </contact>
    <investigator>
      <last_name>Santiago Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic Medical Center</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>fahad.gilani@cmc-nh.org</email>
    </contact>
    <investigator>
      <last_name>Fahad S Gilani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Sammy Elmariah</investigator_full_name>
    <investigator_title>Director, Interventional Cardiology Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

